Trials / Not Yet Recruiting
Not Yet RecruitingNCT06387420
A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
A Phase 1b/2 Study of AK117 (Anti-CD47 Antibody) in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 180 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1b/2 study. All patients are diagnosed with Acute Myeloid Leukemia (AML), Eastern Cooperative Oncology Group (ECOG) performance status 0-3. The purpose of this study is to evaluate the safety and efficacy of AK117 + azacitidine + venetoclax in subjects with AML.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK117 | Subjects receive AK117 intravenously. |
| DRUG | Azacitidine | Subjects receive azacitidine subcutaneously. |
| DRUG | Venetoclax | Subjects receive venetoclax orally. |
| OTHER | Placebo | Subjects receive placebo intravenously. |
Timeline
- Start date
- 2024-04-29
- Primary completion
- 2026-04-01
- Completion
- 2027-04-01
- First posted
- 2024-04-29
- Last updated
- 2024-04-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06387420. Inclusion in this directory is not an endorsement.